Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A

SSZSE:300760
185.38
CNY
+1.08
(+0.59%)
6.77EPS
25.22P/E
195.49BMarket Cap
Apr 23Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.47
8.63
9.09
10.23
12.35
13.62
17.3
20.8
25.1
28.83
30.33
27.47
28.51
Basic EPS, GAAP
1.47
0.98
1.61
2.37
3.34
3.85
5.48
6.59
7.94
9.56
9.64
6.71
6.4
Free Cash Flow per Basic Share
- -
1.54
2.64
2.59
3.01
3.25
6.32
6.25
8.45
6.91
8.65
6.69
- -
Dividend per Share
0.05
3.69
6.56
0.56
0.85
1
1.5
2.5
3.5
8.81
7.22
4.63
4.24
Book Value per Share
8.52
5.83
4.13
6.05
12.46
15.29
19.15
22.17
26.38
27.29
29.57
31.42
34
Tangible Book Value per Share
6.25
3.81
2.01
3.97
10.48
13.31
17.05
16.89
20.87
21
14.59
16.51
19.68
Basic Weighted Avg Shares
925
928
994
1,092
1,114
1,216
1,216
1,215
1,210
1,212
1,211
1,212
1,212
Sales/Revenue/Turnover
7,836
8,013
9,032
11,174
13,753
16,556
21,026
25,270
30,366
34,932
36,726
33,282
34,546
Operating Margin (%)
14.34
12.14
16.85
29.33
30.37
31.03
35.86
35.98
35.13
36.98
35.53
29.86
29.77
Depreciation Expense
- -
316
285
304
331
394
472
700
885
1,010
1,469
1,721
- -
Net Income, GAAP
1,360
910
1,600
2,589
3,719
4,681
6,658
8,002
9,607
11,582
11,668
8,136
7,750
Effective Tax Rate (%)
4.21
13.68
12.93
11.26
12.09
12.73
10.47
11.23
12.26
11.01
9.83
12.64
10.92
Profit Margin (%)
17.35
11.35
17.72
23.17
27.04
28.27
31.66
31.66
31.64
33.16
31.77
24.44
22.43
Working Capital
6,019
1,959
1,735
2,355
10,662
13,505
13,328
12,706
18,836
16,773
15,219
15,811
17,762
LT Debt
1,202
311
1,678
- -
- -
- -
122
152
139
182
178
225
175
Total Equity
9,662
6,538
4,601
6,654
15,167
18,607
23,290
26,968
31,999
33,346
40,758
43,011
46,092
Return on Invested Capital (%)
- -
8.32
16
30.31
31.24
27.39
31.4
31.37
31.99
34.91
31.63
20.44
- -
Return on Capital (%)
- -
9.3
19.88
31.84
31.69
27.69
31.63
31.6
32.34
35.21
31.1
18.58
- -
Return on Common Equity (%)
- -
11.59
29.38
46.49
34.17
27.75
31.81
31.86
32.6
35.6
33.85
22
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
133
126
125
LT Borrowings
- -
- -
- -
LT Finance Leases
210
184
175
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,212
1,212
1,212
Market Capitalization
199,641
164,686
195,487

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
28,054
29,337
30,628
Cash, Cash Equivalents & STI
18,089
18,775
19,857
Accounts Receivable, Net
3,574
3,754
3,573
Inventories
5,254
5,650
5,992
Total Current Liabilities
11,745
12,445
12,866
Payables & Accruals
- -
- -
- -
ST Debt
133
126
125
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.72%
13.28%
5.53%
Free Cash Flow
24.04%
3.56%
-22.59%
Net Income, GAAP
28.07%
6.26%
-30.28%
Sales/Revenue/Turnover
15.8%
10.23%
-9.38%
Total Cash Common Dividend
33.72%
40.83%
-35.78%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,373
11,158
8,954
7,241
36,726
2025
8,237
8,506
- -
7,448
33,282
2026
8,352
9,395
9,350
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.61
3.64
2.54
0.86
9.64
2025
2.17
2.01
- -
0.47
6.71
2026
1.92
2.04
1.97
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1.5
4.07
1.66
7.22
2025
- -
1.97
- -
1.35
4.63
2026
- -
1.56
1.33
- -
- -

Company Description

CEO
Hao Wu
Full Time Employees
21,288
Sector
Health technology
Industry
Medical specialties
Address
Mindray Building Shenzhen GD China 518057
IPO Date
Oct 16, 2018
Business
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. engages in the development, manufacturing, and marketing of advanced medical devices and solutions. The company operates primarily through three core business segments: Patient Monitoring and Life Support, In-Vitro Diagnostic Products, and Medical Imaging Systems. Its product portfolio includes patient monitors, biotelemetry systems, anesthesia delivery systems, defibrillators, electrocardiography (ECG) machines, pulse oximeters, hospital beds, ultrasound systems, hematology analyzers, biochemistry analyzers, reagents, ventilators, and digital laboratory solutions. Mindray serves hospitals, clinics, and diagnostic laboratories globally with a robust presence across major international markets. Founded in 1991 and headquartered in Shenzhen, China, the company has expanded through strategic acquisitions and technological innovation. In recent years, Mindray has made significant advances including the launch of Project 2030 aimed at advancing women's health ultrasound technology with new products such as the Nuewa R9 Platinum featuring 4D super-resolution imaging and broadening global ultrasound education. The company also developed a highly sensitive hs-cTnI cardiac biomarker assay improving myocardial injury diagnostics. A major strategic move in 2024 was Mindray's $927 million acquisition to gain control of APT Medical, a specialized cardiovascular medical device firm, enhancing its capabilities and market penetration in cardiovascular technologies and consumables. Additionally, Mindray has established a strategic cooperation with Inpeco to augment laboratory automation solutions. These developments reflect Mindray's focus on expanding its product offerings, strengthening its global market presence, and enhancing integrated solutions in patient monitoring, diagnostics, and imaging technologies.